CURIS INC
Company Information
Industry
Biological Products, (No Diagnostic Substances)
SIC Code
2836
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
128 SPRING STREET, LEXINGTON, MA, 02421
Mailing Address
128 SPRING STREET, LEXINGTON, MA, 02421
Phone
617-503-6500
Fiscal Year End
1231
EIN
043505116
Financial Overview
FY2025
$-0.58
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 4 Insider stock transaction report | April 1, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | March 27, 2026 | View on SEC |
| 10-K Annual financial report | March 24, 2026 | View on SEC |
| 4 Insider stock transaction report | March 23, 2026 | View on SEC |
| 4 Insider stock transaction report | March 23, 2026 | View on SEC |
| 4 Insider stock transaction report | March 23, 2026 | View on SEC |
| 4 Insider stock transaction report | March 23, 2026 | View on SEC |
| 4 Insider stock transaction report | March 23, 2026 | View on SEC |
| 8-K Current report of material events | March 19, 2026 | View on SEC |
| 4 Insider stock transaction report | March 18, 2026 | View on SEC |
Annual Reports
10-K
March 24, 2026
- Advancing emavusertib through clinical trials for AML and MDS blood cancers.
- Steady royalty income stream from the skin cancer drug Erivedge.
Material Events
8-K
Other
March 19, 2026
High Impact
- Emavusertib shows promising clinical data, including 100% objective response rate (ORR) in previously untreated PCNSL patients (n=3) and the initiation of a new Phase 2 trial for CLL.
- Secured $20.2 million in new funding from a share sale, with potential for another $20.2 million upon hitting a clinical goal.
8-K
Legal Issue
February 9, 2026
High Impact
- CURIS INC successfully secured its continued listing on the Nasdaq Global Market, avoiding delisting.
- The company regained full compliance with Nasdaq's Market Value of Listed Securities (MVLS) Rule.
Insider Trading
BUY
1 insiders
1 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2836)
Kodiak Sciences Inc.
KOD
Biological Products, (No Diagnostic Substances)
BioAtla, Inc.
BCAB
Biological Products, (No Diagnostic Substances)
Cardiff Oncology, Inc.
CRDF
Biological Products, (No Diagnostic Substances)
HALOZYME THERAPEUTICS, INC.
HALO
Biological Products, (No Diagnostic Substances)
Adaptive Biotechnologies Corp
ADPT
Biological Products, (No Diagnostic Substances)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.